Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Trial Title: Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

NCT ID: NCT06008119

Condition: Colorectal Cancer Metastatic

Conditions: Official terms:
Colorectal Neoplasms
Bevacizumab
Cetuximab
Vemurafenib

Conditions: Keywords:
BRAFV600E mutant

Study type: Interventional

Study phase: Phase 3

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Tunlametinib plus Vemurafenib
Description: 12mg BID Tunlametinib+720mg BID Vemurafenib
Arm group label: Experimental

Intervention type: Drug
Intervention name: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
Description: According to investigators' suggestion
Arm group label: Control

Summary: This is a multicenter, randomized, open-label, 3-arm Phase 3 study

Detailed description: This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate Tunlamatinib plus Vemurafenib versus Investigator's choice of Chemotherapy based treatment as controls in patients with BRAFV600E mutant Metastatic Colorectal Cancer (CRC) whose disease has progressed after 1 or more prior regimens in the metastatic setting.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Inclusion Criteria: 1. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures. 2. Male or female patients with 18 to 70 years of age at time of informed consent; 3. Histological or cytologically confirmed metastatic CRC 4. Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory (BRAFV600 is permitted) 5. Able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archival or newly obtained) for confirmatory central laboratory testing of BRAF mutation status. 6. Progression of disease after 1 or more prior regimens in the metastatic setting 7. At least 1 site of radiographically measurable disease by RECIST 1.1 8. Eastern Cooperative Oncology Group (ECOG) Performance Status(PS) of 0 to 1; 9. Life expectancy ≥ 3 months; 10. Can swallow the medicine, 11. Adequate hematologic, renal, cardiac and liver function as defined by laboratory values performed within 7 days prior to initiation of dosing: 12. Be willing and able to complete all the study procedures and follow-up examinations. Exclusion Criteria: - Exclusion Criteria: 1. Prior treatment with any BRAF and MEK inhibitor; 2. Known contraindication to receive the treatment of control arm (according to latest PI). 3. Symptomatic brain metastasis or leptomeningeal disease 4. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization 5. Known history of acute or chronic pancreatitis 6. Uncontrolled GI bleeding, Dysphagia，refractory nausea, vomiting, small bowel resection or any other gastrointestinal ailment that would preclude study drug absorption. 7. Serious cardiovascular disease , including uncontrolled congestive heart failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia , deep vein thrombosis or pulmonary emboli or cerebrovascular events ≤ 6 months prior to starting study treatment; 8. History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes) 9. Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy) 10. Uncontrolled blood pressure despite medical treatment 11. Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy 12. Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy 13. Anti-HIV(+) , Anti-TP( +); Active hepatitis B or hepatitis C infection .......

Gender: All

Minimum age: 18 Years

Maximum age: 70 Years

Healthy volunteers: No

Start date: November 24, 2023

Completion date: December 24, 2026

Lead sponsor:
Agency: Shanghai Kechow Pharma, Inc.
Agency class: Industry

Source: Shanghai Kechow Pharma, Inc.

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06008119